The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Aventador:
Regarding your comment to and about ALBI1 - that was rather impolite, wasn't it? Did he really deserve it?
Aventador:
Gracias amigo. Feliz Navidad.
Nota:
I think you are confusing the end of the PK Study at the end of Q1, 2022, with the conclusion of the P3 trial of Lupuzor which will not start until after the conclusion of the PK Study,
Therefore, because the P3 Trial will not start until Q2, 2022, at the earliest, I would not expect the conclusion of that Trial before late 2023.
The CIDP 2/3 Trial also will not start until the successful conclusion of the P140/Lupuzor PK Study at the end of Q1, 2022. Hopefully it will start around the same time as the P3 Lupuzor trial but will be concluded earlier than the Lupuzor one because of a shorter trial process. Hence it is hoped to bring it earlier to the market.
In both cases, expect to hear news on the trials from time to time. Let's hope it will be positive.
We are also promised news of progress of the Anti-infectives, particularly BioAMB, especially on the co-funding front.
So I would expect positive news flow and upward movement of the SP next year.
Fingers crossed.
Fifi + Nota
The only item that was new in Tim's interview yest was concerning the subs for shares by Avion's parent and Lansdown.
I guess that Alora's investment was partly recognition of IMM's investment in producing a new, improved version of Lupuzor/P140 which must cost quite a few bucks and it also shows their commitment to the P3 Lupuzor trial.
However, in the review of IMM's research programme programme in the RNS of 19 November, it was made perfectly clear that the recruitment of participants in the PK study would not be completed until December, with dosing commencing in January and announcement of results at end of Q1. So don't get your hopes up about early news on anything connected with Lupus or CIDP until Q2 or H2 of 2022. Nevertheless looks like being a good year for IMM not forgetting news on other fronts.
It makes me laugh reading Lambo's bleatings about the warrants that have been issued as being over-generous. Had he or any of us been offered these conditions (shares priced at 11p, etc) would any of us have seen them as generous given that we were at that moment able to buy shares at about half that price?
Nolupus -
A PR job with IMM - what a good idea!
Nolupus:
I go along with Aventador in agreeing with Nolupus although not necessarily relying only on Dr Zimmer as the largest shareholder objecting to any takeover while IMM's share price is so low.
A close reading of the RNS of 18th November shows the confidence the Board in the details they provide of several important developments in the various programmes that IMM is working on: for example, the improved version of P140,
the progress on CIDP research and negotiations with 2 possible commercial collaborators with commercialisation possibly moving ahead of Lupuzor;
the confidence in a successful PK trial on P140; the progress on the anti-infective BioAMB and the negotiations with 2 possible commercial partners.
Finally, the closer and expanded agreement with CNRS for licensing P140 and the closer involvement of Prof Sylviane Muller in the P140 platform's possibilities.
All of these developments do not seem like IMM is a company on the brink of giving up as an independent pharma company. Rather it indicates a confidence on the part of the BOD that the company is close to making important breakthroughs in its research objectives.
I'm sure Dr Zimmer and other important shareholders know all this. Are they willing to sell out at this stage? I hope not.
Aventador:
I wouldn't spend too much time on ALB1. At least he and others like him are helping to keep the SP at its present record-low level. The shares IMO are an extraordinary bargain.
Better to go back to the RNS of 18 November - "the Evolution of Immupharma" and take a look at the new sense of drive and ambition that underlines it. I think it is especially meaningful that the collaboration agreement between IMM and CNRS and Prof. Muller has been strengthened, that she is taking a close interest in the development of the CIDP 2/3 trial preparations and that they are being joined in this with the leading CIDP specialist in France in this field, Prof. de Seze. And there is much else in the RNS that makes exciting reading for LTH of IMM.
All this is going to require more working capital unless CRNS is paying for some of the research. I can't believe that IMM has not worked out where this finance is coming from before agreeing these initiatives.
My personal view is that although Prof Muller has won many academic awards for her work on peptides in general and on P140/Lupuzor in particular, she must be feeling frustrated ( to put it politely) at the lack of progress on Lupuzor, CIDP and other medical applications of P140. Hence the decision for her and CRNS to become more closely involved in IMM's R and D.
After all, it would be the crowning achievement of her professional career and her lasting legacy if success in the lab is converted into real life improvement for the many thousands who suffer from Lupus, CIDP and other diseases of the autoimmune system.
ALB1.
A change of tune from you. Much appreciated.
I notice from a post you sent a few days ago that you were accusing the BOD of being only interested in keeping up their lifestyles. Has it never occurred to you that maybe, just maybe, they are more committed to the success of IMM than you or I can possibly be. Yes, we have money at stake, but the BOD and all who work for IMM have their careers and reputations at stake as well.
Might it not be possible that they are working their guts out not only for the success of our investment but also for the millions of lupus sufferers and others (like CIDP patients) whose lives will be hugely improved if their research is successful. Moreover, if they are successful it will be a big boost to their professional reputations and careers.
So stop knocking them! Try a little patience!
It's hard to get away from the conviction that ALB1 and his followers are no other than imitations of Private Fraser, the dour undertaker in Dad's Army who near the beginning of most episodes would intone "WE'RE DOOMED, DOOMED!". And at the end, when all turned out well thanks to the fortitude of his fellow members of the local Home Guard, would tell anyone who would listen "I always said that it would turn out all right!"
Myy prediction is that around the middle of 2022, when IMM has completed the PK Study and the Phase 3 of Lupuzor is underway, when a commercial partner has come on board to give impetus to the CIDP programme and another partner has been found to launch the BioAMP product, the same doomsters will be telling us that they predicted this success all the time.
So as Nolupus advised, let them get on with it instead of constantly sniping at them.
After reading the last 2 RNS notices which both confirmed the strong science behind the IMM R and D, I have been perplexed by the negative price reaction. Whlle I can understand the disappointment at the postponement of the PK study results the explanation of it indicates valid scientfic reasons for it, namely to produce an improved version of Lupuzor that will be tested in the study. It's not as though IMM has been doing nothing during the past 4 months. Instead, there is a positivity in these two RNS announcements that has been lacking in the previous two years.
The RNS concerning the collaboration with Imperial College in encouraging. Would a topline British research institute agree to this if it doubted the science excellence of IMM's labs in Bordeauxs or was unsure if IMM has the capacity to pay for Imperial's advice? I don't think so.
Which is why I continue to buy this stock; the science is excellent and the money will be forthcoming in the opinion of those who truly have inside information of the situation.
cubasteve:
I sympathise with your feelings. I've been taken aback by the hostility to the most recent RSN of most of the contributors to this BB. I thought the RNS contained rather good news apart from the delay to the PK Study for entirely plausible reasons. I welcome the news about the CIDP study especially the close involvements of Professors Muller and de Seze.
My main concern is the financial of position of IMM and its capacity to continue its R and D until it finds commercial partners to share the financial burden. A futher RNS on this point would be welcome.
Otherwise, I guess the best advice is to ignore this BB for the next 3 months and see what transpires. As a shareholder you should receive any new RNS that comes along in this period - the only source of reliable information about IMM. No outsider really has a clue.
If you want to buy/sell, set your stop orders and take a holiday!
ATB.
The first line should have read "to give the new team time".
Nolupus:
Very sensible advice re patience to give the new time to achieve results. But like you, I'd like to hear about Sol (weren't we told to expect exciting news by Xmas?) and the the Tim prediction of the "cash runway" until 2023. Does the runway still extend that far?
Jonah58
Of all the posts today yours is the most interesting. Thank you for the insight into the possible efficacy of BioAMB and its market potential.
At last we have a transparent picture of what is involved in preparing for the PK Study and what looks like a definite timeline for it. We have been spared the vague and misleading pronouncements of Tim McC who did not let on that the commencement of the Study could take 4 months. Maybe the Board has insisted in much fuller disclosure of what is going on not just with Lupuzor but also with the other products in the pipeline.
The prospects are looking much better for IMM and its shareholders.
I pity poor Lambo who has now returned to his gloom-filled warnings of the CLN repayment - how many times can he repeat himself? I hope he sells his IMM shares and transfers his attention elsewhere.
Nolupus:
Tim has been telling us that Sol, the cancer preventant sun cream, has been making good progress more than once over a period of several months. If this is good progress means I hate to think what poor progress would mean.
The mystery suitors who might bring this to market and pay Incanthera big bucks are unknown to us. I would be surprised if one of them is Avion. More likely they are already big players in the sun cream market.
Pokerchips:
Thanks for your interesting post on Tim McC.
Have you considered that he may have become a mere figurehead? Maybe Avion is not keeping him up to date on the PK Study. Perhaps they have told him that it is a waste of his and their time for him to visit the US. Perhaps some of their directors plan instead to visit the Ureka labs in Bordeaux to see for themselves what they are doing there and if it might prove interesting for Avion to take a financial interest . Perhaps they would like to speak to a real scientist like Prof Sylviane Muller who is said to be working on a Phase 2/3 trial of P140 for treating CIDP which could fit the Avion product portfolio.
I think you should ask Lisa for information of what is really going on. Perhaps she can give you a few pointers.
Finally, I definitely agree with you that in this new transparency age of IMM we are due an update. The lack of one is a cause of considerable concern in the light of the assurances that Tim gave in his Proactive interview in early October. It would convey more credibility if it came from Tim Franklin rather that Tim McC.
MysticMike
I don't think this delay has anything to do with Tim and whether he cares about his shareholders.
More likely it is to do with Avion's strategy for handling the Phase 3 Lupuzor trial which they want to discuss in Europe with IMM's leading scientists like Prof. Sylviane Muller. They may also wish to discuss other products in the IMM/Ureka pipeline such as the use of peptide140 (known as Lupuzor for the treatment of Lupus) for various diseases of the immune system such as CIDP.
We are likely to hear the results of this meeting, I guess, before the end of this year. We have no way of telling whether good news or bad will come from this meeting. I incline to be optimistic because I find it hard to believe that Avion's bosses will come to Europe solely to kick Tim and Co in the pants. They could do so much more cheaply by Zoom or email.
Mystic Mike:
History seldom repeats itself. I hold no great hopes for a positive RNS from IMM before the end of this month but I do have hopes that we shall hear something before Christmas. Surely there will be news of the PK trial and about Ureka research activities by then. Is that too much to hope for?
Lambo222.
You are a manic-depressive. On Tuesday you were talking about an "epic" rise to 170p after a couple of substantial buys.
Now you seem to be on the 5p track. Nuts!
No doubt the actuality will be somewhere in the middle after we get an update on the Avion/IMM front. If it's good we can maybe look forward to the price edging upwards but the degree of the increase will depend on the detail of the RNS.
Some meaningful large buys today.
Perhaps someone has heard that Avion are sending a team to Europe to meet the IMM team within a few weeks instead of Tim going to the USA.